Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Crohns Colitis ; 14(4): 480-489, 2020 May 21.
Article in English | MEDLINE | ID: mdl-31602473

ABSTRACT

BACKGROUND: Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear. METHODS: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician. RESULTS: We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn's disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients. CONCLUSIONS: ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.


Subject(s)
Anti-Inflammatory Agents , Drug-Related Side Effects and Adverse Reactions , Inflammatory Bowel Diseases , Lung Diseases, Interstitial , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/classification , Comorbidity , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/therapy , Female , Global Health/statistics & numerical data , Glucocorticoids/administration & dosage , Hospitalization/statistics & numerical data , Humans , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/epidemiology , Inflammatory Bowel Diseases/therapy , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/epidemiology , Lung Diseases, Interstitial/therapy , Lung Transplantation/methods , Lung Transplantation/statistics & numerical data , Male , Middle Aged , Outcome and Process Assessment, Health Care , Symptom Assessment/statistics & numerical data
2.
Dig Liver Dis ; 50(12): 1299-1304, 2018 12.
Article in English | MEDLINE | ID: mdl-30077465

ABSTRACT

BACKGROUND: Real-life data on vedolizumab effectiveness in inflammatory bowel disease (IBD) are still emerging. Data on the comparative safety of the gut selective profile are of particular interest. AIMS: To assess clinical outcome and safety in IBD patients treated with vedolizumab. METHODS: We retrospectively collected data of patients treated with vedolizumab at eight UK hospitals (August 2014-January 2018). Clinical response and remission at 14 and 52 weeks evaluated through Physician Global Assessment (PGA) and adverse events were recorded. Possible predictors of clinical response were examined. RESULTS: Two hundred and three IBD patients (mean treatment 16 ±â€¯8 months) were included. Of these, 135 patients (mean age 40.6 ±â€¯16.0 years; F:M 1.9:1) had CD and 68 (mean age 44.5 ±â€¯18.1 years; F:M 1:1.2) had UC. According to PGA, 106/135 (78.5%) CD and 62/68 (91.2%) UC patients (p = 0.02) had a clinical response/remission at 14 weeks, whereas 76/119 (63.9%) CD and 52/63 (82.5%) UC patients (p < 0.01) showed a sustained response or remission at 52 weeks, with a high adherence rate (97%). No predictors of clinical response were found. The cumulative incidence of infectious diseases was 11.9 per 100 person-years. CONCLUSION: Vedolizumab is an effective therapy for inducing and maintaining remission of IBD, with better results for UC, and with a good safety profile.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Gastrointestinal Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Medication Adherence/statistics & numerical data , Adult , Female , Humans , Male , Middle Aged , Remission Induction , Retrospective Studies , United Kingdom , Young Adult
3.
Dig Dis ; 35(5): 444-448, 2017.
Article in English | MEDLINE | ID: mdl-28334707

ABSTRACT

BACKGROUND: No study has compared changes in quality of life (QoL) following iron therapy between anemic and non-anemic, hypoferritinemic patients. This study compares the impact of parenteral iron replacement on QoL in inflammatory bowel disease (IBD) patients with anemia, or in those with hypoferritinemia alone. METHODS: Consecutive IBD patients diagnosed with anemia or hypoferritinemia were enrolled. IBD questionnaire (IBDQ) and 36-Item Short Form Survey (SF36) at diagnosis and 6 weeks post treatment were measured. RESULTS: Ten patients with anemia and 13 with hypoferritinemia were treated with intravenous iron polymaltose. Across all patients, there was a significant improvement in median SF36 mental component score by 8.5 (p = 0.004) and median IBDQ by 12 (p = 0.02). There was a trend towards improved median SF36 physical component score by 3.2 (p = 0.6). These changes were not significantly different when comparing anemic with hypoferritinemic patients. In IBDQ, there was a trend toward greater improvement in hypoferritinemic vs. anemic patients (20 vs. 1.5, p = 0.31). CONCLUSIONS: This is the first study to show that improvements in QoL in hypoferritinemic patients are similar to those with anemia. Based on these results, patients with IBD should be offered the option of iron therapy when they are found to be hypoferritinemic, even in the absence of anemia.


Subject(s)
Anemia/complications , Anemia/drug therapy , Ferritins/blood , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Iron/administration & dosage , Iron/therapeutic use , Quality of Life , Administration, Intravenous , Adult , Aged , Anemia/blood , Female , Humans , Inflammatory Bowel Diseases/blood , Iron/pharmacology , Male , Middle Aged , Surveys and Questionnaires
4.
N Z Med J ; 128(1423): 63-76, 2015 Oct 16.
Article in English | MEDLINE | ID: mdl-26645757

ABSTRACT

The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging. The development of newer medical therapies has increased the options for managing patients in this situation, but access and funding remain limited. This guideline summarises the literature regarding this situation and provides guidance as to the management of refractory colitis in the New Zealand setting.


Subject(s)
Colitis, Ulcerative/therapy , Adalimumab/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Appendectomy , Azathioprine/therapeutic use , Cyclosporine/therapeutic use , Drug Resistance , Drug Therapy, Combination , Fecal Microbiota Transplantation , Gastrointestinal Agents/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Infliximab/therapeutic use , Leukapheresis , Mercaptopurine/therapeutic use , Mesalamine/therapeutic use , Methotrexate/therapeutic use , New Zealand , Pediatrics , Piperidines/therapeutic use , Proctocolectomy, Restorative , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Recurrence , Severity of Illness Index , Tacrolimus/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors
5.
Environ Monit Assess ; 186(8): 4857-70, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24687690

ABSTRACT

An extensive field survey was employed for assessing the impacts of long-term wastewater irrigation of forage crops and orange orchards in three suburban agricultural areas in Cyprus (areas I, II, and III), as compared to rainfed agriculture, on the soil geochemical properties and the bioaccumulation of heavy metals (Zn, Ni, Mn, Cu, Co) to the agricultural products. Both ryegrass fields and orange orchards in areas I and II were continuously wastewater irrigated for 10 years, whereas clover fields in area III for 0.5, 4, and 8 years. The results revealed that wastewater reuse for irrigation caused a slight increase in soil salinity and Cl(-) content in areas I and II, and a remarkable increase, having strong correlation with the period in which wastewater irrigation was practiced, in area III. Soil salinization in area III was due to the high electrical conductivity (EC) of the wastewater applied for irrigation, attributed to the influx of seawater to the sewage collection network in area III. In addition, the wastewater irrigation practice resulted in a slight decrease of the soil pH values in area III, while a subtle impact was identified regarding the CaCO3, Fe, and heavy metal content in the three areas surveyed. The heavy metal content quantified in the forage plants' above-ground parts was below the critical levels of phytotoxicity and the maximum acceptable concentration in dairy feed, whereas heavy metals quantified in orange fruit pulp were below the maximum permissible levels (MPLs). Heavy metal phytoavailability was confined due to soil properties (high pH and clay content), as evidenced by the calculated low transfer factor (TF).


Subject(s)
Agriculture/methods , Metals, Heavy/analysis , Soil Pollutants/analysis , Soil/chemistry , Waste Disposal, Fluid/methods , Cyprus , Environmental Monitoring , Sewage/chemistry , Wastewater/chemistry , Wastewater/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...